SA519401020B1 - مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2 - Google Patents

مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2

Info

Publication number
SA519401020B1
SA519401020B1 SA519401020A SA519401020A SA519401020B1 SA 519401020 B1 SA519401020 B1 SA 519401020B1 SA 519401020 A SA519401020 A SA 519401020A SA 519401020 A SA519401020 A SA 519401020A SA 519401020 B1 SA519401020 B1 SA 519401020B1
Authority
SA
Saudi Arabia
Prior art keywords
benzamides
phenylsulfonyl
cell lymphoma
related compounds
protein inhibitors
Prior art date
Application number
SA519401020A
Other languages
English (en)
Inventor
جيانيونج شين
شاومينج وانج
Original Assignee
ذا ريجينتس اوف ذا يونيفيرسيتى اوف ميتشجين
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ذا ريجينتس اوف ذا يونيفيرسيتى اوف ميتشجين filed Critical ذا ريجينتس اوف ذا يونيفيرسيتى اوف ميتشجين
Publication of SA519401020B1 publication Critical patent/SA519401020B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

يوفر الإختراع الحالي مركبات لها الصيغة I-A: وأملاح مقبولة صيدليًا وذوابات solvates مما سبق، حيث تكون A، X1، X2، X3 R1a، R1bE، و= كما هو محدد في الوصف. يوفر الإختراع الحالي أيضًا مركبات لها الصيغة I-A للاستخدام لعلاج مرض، اضطراب، أو حالة مرضية تستجيب لتثبيط البروتين ليمفوما الخلية البائية 2 B-cell lymphoma 2 (Bcl-2) مثل السرطان cancer. شكل1
SA519401020A 2016-08-05 2019-02-04 مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2 SA519401020B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US201762454101P 2017-02-03 2017-02-03
PCT/US2017/045428 WO2018027097A1 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
SA519401020B1 true SA519401020B1 (ar) 2022-03-16

Family

ID=59677319

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519401020A SA519401020B1 (ar) 2016-08-05 2019-02-04 مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2

Country Status (26)

Country Link
US (3) US10829488B2 (ar)
EP (3) EP3569601B1 (ar)
JP (2) JP6651180B2 (ar)
KR (2) KR102376764B1 (ar)
CN (2) CN109311871B (ar)
AU (2) AU2017305508B2 (ar)
BR (1) BR112019001666A2 (ar)
CA (1) CA3031419C (ar)
CY (1) CY1123859T1 (ar)
DK (1) DK3494115T3 (ar)
ES (1) ES2849959T3 (ar)
HR (1) HRP20202073T1 (ar)
HU (1) HUE053414T2 (ar)
IL (2) IL264059B (ar)
LT (1) LT3494115T (ar)
MX (2) MX2019001391A (ar)
PE (1) PE20190711A1 (ar)
PH (1) PH12019500231A1 (ar)
PT (1) PT3494115T (ar)
RS (1) RS61821B1 (ar)
RU (3) RU2744358C2 (ar)
SA (1) SA519401020B1 (ar)
SG (2) SG11201900135YA (ar)
SI (1) SI3494115T1 (ar)
WO (1) WO2018027097A1 (ar)
ZA (2) ZA201900240B (ar)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
MX2019001391A (es) * 2016-08-05 2019-06-06 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
RS63603B1 (sr) 2017-04-18 2022-10-31 Shanghai Fochon Pharmaceutical Co Ltd Sredstva za indukciju apoptoze
CA3098348A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 inhibitors
GEP20237458B (en) * 2018-07-31 2023-01-10 Ascentage Pharma Suzhou Co Ltd Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
UA125241C2 (uk) * 2018-07-31 2022-02-02 Есентейдж Фарма (Сучжоу) Ко., Лтд. СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP
CN110772521A (zh) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3095699A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
TWI732353B (zh) * 2018-11-23 2021-07-01 大陸商蘇州亞盛藥業有限公司 藥物組成物及其用途
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
WO2021000899A1 (en) * 2019-07-02 2021-01-07 Ascentage Pharma (Suzhou) Co., Ltd. A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF
AU2020321068A1 (en) * 2019-07-31 2021-03-18 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US20220317127A1 (en) * 2019-11-27 2022-10-06 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
TWI772992B (zh) * 2019-12-03 2022-08-01 大陸商蘇州亞盛藥業有限公司 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
US20220323465A1 (en) * 2019-12-04 2022-10-13 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
WO2021113497A1 (en) 2019-12-06 2021-06-10 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
US20230159518A1 (en) * 2020-03-06 2023-05-25 Ascentage Pharma (Suzhou) Co., Ltd. Crystalline forms or amorphous forms of n-(phenyl sulfonyl) benzamide compounds or its salts or solvates
WO2021180040A1 (zh) * 2020-03-12 2021-09-16 南京明德新药研发有限公司 苯并五元环类化合物
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
EP4180422A4 (en) * 2020-07-10 2024-01-24 Jiangsu Hengrui Pharmaceuticals Co Ltd SULFONYL BENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PROCESS THEREOF AND USE THEREOF
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
EP4199924A1 (en) * 2020-08-21 2023-06-28 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
JP2024504542A (ja) * 2021-02-01 2024-02-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CN117957018A (zh) 2021-08-02 2024-04-30 苏州亚盛药业有限公司 一种药物组合及其用途
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
BRPI0719563A2 (pt) 2006-12-04 2013-12-10 Abbott Lab Ensaios diagnósticos amigáveis para terapia de câncer
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EP3101019A1 (en) 2008-12-05 2016-12-07 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP3095784A1 (en) 2009-01-19 2016-11-23 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102388151A (zh) 2009-02-11 2012-03-21 雅培制药有限公司 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物
CN109897038B (zh) * 2009-05-26 2022-04-05 艾伯维爱尔兰无限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CN103167867B (zh) 2010-10-29 2016-12-21 Abbvie 公司 含有细胞凋亡诱导药剂的固体分散体
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
SI2642999T1 (sl) 2010-11-23 2017-01-31 Abbvie Ireland Unlimited Company Postopki zdravljenja z uporabo selektivnih Bcl-2 inhibitorjev
US10327687B2 (en) 2015-12-30 2019-06-25 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
MX2019001391A (es) 2016-08-05 2019-06-06 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Also Published As

Publication number Publication date
ES2849959T3 (es) 2021-08-24
ZA201900240B (en) 2020-05-27
SG10201913643YA (en) 2020-03-30
KR20190035710A (ko) 2019-04-03
ZA201908466B (en) 2020-05-27
KR20210107170A (ko) 2021-08-31
CN110483501A (zh) 2019-11-22
EP3494115B1 (en) 2020-10-21
CA3031419C (en) 2021-08-24
AU2017305508B2 (en) 2021-01-07
DK3494115T3 (da) 2021-01-18
RU2722560C1 (ru) 2020-06-01
RS61821B1 (sr) 2021-06-30
US20190315739A1 (en) 2019-10-17
IL264059B (en) 2021-05-31
AU2021202113B2 (en) 2022-08-18
US20180354950A1 (en) 2018-12-13
EP3569601A2 (en) 2019-11-20
AU2017305508A1 (en) 2019-02-07
SI3494115T1 (sl) 2021-02-26
MX2020013014A (es) 2021-02-22
NZ750100A (en) 2021-01-29
RU2020114660A3 (ar) 2020-09-15
US10829488B2 (en) 2020-11-10
RU2020134802A (ru) 2022-04-25
BR112019001666A2 (pt) 2019-05-28
WO2018027097A1 (en) 2018-02-08
HRP20202073T1 (hr) 2021-02-19
JP2020007311A (ja) 2020-01-16
EP3569601B1 (en) 2022-06-22
CA3031419A1 (en) 2018-02-08
EP3494115A1 (en) 2019-06-12
JP6651180B2 (ja) 2020-02-19
CY1123859T1 (el) 2022-05-27
US10221174B2 (en) 2019-03-05
KR102376764B1 (ko) 2022-03-18
IL282099B (en) 2022-03-01
RU2020114660A (ru) 2020-06-19
CN109311871B (zh) 2020-02-28
KR102429704B1 (ko) 2022-08-04
RU2744358C2 (ru) 2021-03-05
LT3494115T (lt) 2021-01-25
CN110483501B (zh) 2022-07-01
CN109311871A (zh) 2019-02-05
PT3494115T (pt) 2021-01-15
PE20190711A1 (es) 2019-05-17
IL264059A (en) 2019-01-31
US20210002277A1 (en) 2021-01-07
EP4129999A1 (en) 2023-02-08
SG11201900135YA (en) 2019-02-27
EP3569601A3 (en) 2019-11-27
MX2019001391A (es) 2019-06-06
JP7205903B2 (ja) 2023-01-17
HUE053414T2 (hu) 2021-06-28
AU2021202113A1 (en) 2021-05-06
IL282099A (en) 2021-05-31
PH12019500231A1 (en) 2019-07-29
US11718613B2 (en) 2023-08-08
JP2019527705A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
SA519401020B1 (ar) مركبات n-(فينيل سلفونيل)بنزاميد والمركبات ذات الصلة كمثبطات لبروتين ليمفوما الخلية البائية 2
WO2017176957A8 (en) Mdm2 protein degraders
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
MX2023006257A (es) Inhibidores de smyd.
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
MX2019002303A (es) Inhibidores de procesos metabolicos celulares.
PH12016501972A1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
EA201591781A1 (ru) Химические соединения
MX2018004664A (es) Antagonistas de ep4.
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
PH12021550374A1 (en) Small molecule menin inhibitors
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
JOP20190163B1 (ar) منشط nrf2
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2016016769A (es) Compuestos, composicion farmaceutica y su uso en el tratamiento de enfermedades neurodegenerativas.
PH12019500368A1 (en) Inhibitors of cellular metabolic processes